ANI Pharmaceuticals surges on earnings beat led by Cortrophin Gel
Rare disease drugmaker exceeds analyst expectations with record Q4 revenue and reaffirms 2026 outlook
ANI Pharmaceuticals delivered a stronger-than-expected fourth quarter, driven by explosive growth in its flagship rare disease treatment, as the specialty pharmaceutical company continues its transformation from generic drugmaker to focused biopharmaceutical firm.
The Minnesota-based company reported adjusted earnings per share of $2.33 for the fourth quarter of 2025, significantly exceeding analyst estimates that ranged from $1.99 to $2.02. Revenue reached $247.1 million, marking a 29.6% increase from the prior year and beating Wall Street projections of approximately $233 million.
The standout performer was Purified Cortrophin Gel, a treatment for multiple sclerosis and other autoimmune conditions, which surged 87.6% year-over-year to $111.4 million in quarterly revenue. This growth propelled the company's Rare Disease segment to $131.3 million in sales, a 50.8% increase from the same period last year. For the full year, Cortrophin Gel generated $347.8 million in revenue, up 75.6% from 2024.
"We delivered record quarterly and full year net revenues, and record quarterly and full year adjusted non-GAAP EBITDA, reflecting the strength of our diversified portfolio and our commercial execution," the company stated in its earnings announcement.
Full-year 2025 revenue climbed 43.8% to $883.4 million, while adjusted non-GAAP earnings per share reached $7.89. The company also posted record quarterly adjusted EBITDA of $65.4 million, up 30.6% from the previous year, and full-year adjusted EBITDA of $229.8 million, representing a 47.3% increase.
ANI Pharmaceuticals reaffirmed its 2026 financial guidance, projecting total net revenue between $1.055 billion and $1.115 billion, representing 19-26% growth. The company expects Cortrophin Gel revenue to reach $540 million to $575 million, with adjusted EPS ranging from $8.83 to $9.34.
Analysts maintain a positive outlook on the stock, with a consensus rating of "Moderate Buy" and an average price target of $110.50, according to MarketBeat data. This target represents approximately 43% upside from the stock's recent trading level around $77.
The company's strategic shift toward rare disease therapeutics has been paying off, with the Rare Disease segment now accounting for nearly half of total revenue. Analysts have noted the successful transformation, with several firms recently upgrading their price targets ahead of the earnings release.
Shares of ANI Pharmaceuticals have gained ground in recent months, though the stock remains well below its 52-week high of $99.50. The company's market capitalization stands at approximately $1.7 billion, with a relatively low beta of 0.50, suggesting the stock is less volatile than the broader market.
Investors will be watching the company's ability to maintain its momentum in the Cortrophin Gel franchise while successfully integrating its diverse portfolio of generic and branded products. The reaffirmed 2026 guidance suggests management confidence in continued growth despite potential competitive pressures in the pharmaceutical market.